In the first study providing data on the therapeutic efficacy of long-term STN-DBS in PD due to heterozygous GBA mutations, among 98 PD patients treated with STN-DBS, three GBA mutation carriers (one GBA N370S and two GBA L444P) were detected and followed for up to 10 years. Here, GBA1 is linked to Parkinson disease.